- Home
- NSTS vs MDXH Comparison
NSTS vs MDXH Comparison
Compare NSTS & MDXH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NSTS
- MDXH
- Stock Information
- Founded
- NSTS 1921
- MDXH 2003
- Country
- NSTS United States
- MDXH Belgium
- Employees
- NSTS N/A
- MDXH N/A
- Industry
- NSTS Savings Institutions
- MDXH
- Sector
- NSTS Finance
- MDXH
- Exchange
- NSTS Nasdaq
- MDXH Nasdaq
- Market Cap
- NSTS 65.8M
- MDXH 73.3M
- IPO Year
- NSTS N/A
- MDXH 2021
- Fundamental
- Price
- NSTS N/A
- MDXH $1.60
- Analyst Decision
- NSTS
- MDXH Buy
- Analyst Count
- NSTS 0
- MDXH 1
- Target Price
- NSTS N/A
- MDXH $6.00
- AVG Volume (30 Days)
- NSTS 2.7K
- MDXH 42.3K
- Earning Date
- NSTS 05-12-2025
- MDXH 04-30-2025
- Dividend Yield
- NSTS N/A
- MDXH N/A
- EPS Growth
- NSTS N/A
- MDXH N/A
- EPS
- NSTS N/A
- MDXH N/A
- Revenue
- NSTS $8,931,000.00
- MDXH $90,049,000.00
- Revenue This Year
- NSTS N/A
- MDXH $23.38
- Revenue Next Year
- NSTS N/A
- MDXH $16.84
- P/E Ratio
- NSTS N/A
- MDXH N/A
- Revenue Growth
- NSTS 82.49
- MDXH 28.29
- 52 Week Low
- NSTS $9.37
- MDXH $1.35
- 52 Week High
- NSTS $13.32
- MDXH $3.50
- Technical
- Relative Strength Index (RSI)
- NSTS 60.88
- MDXH 54.49
- Support Level
- NSTS $10.80
- MDXH $1.51
- Resistance Level
- NSTS $12.22
- MDXH $1.64
- Average True Range (ATR)
- NSTS 0.26
- MDXH 0.08
- MACD
- NSTS 0.12
- MDXH 0.02
- Stochastic Oscillator
- NSTS 98.45
- MDXH 85.71
About NSTS NSTS Bancorp Inc.
NSTS Bancorp Inc is a savings and loan holding company regulated Federal Reserve Board. The company was formed to serve as the North Shore Trust and Savings stock holding company. The Bank is a wholly-owned subsidiary of the company and operates as a traditional savings institution focused on serving the banking needs of customers in our market area of Lake County, Illinois and adjacent communities.
About MDXH MDxHealth SA
MDxHealth SA is a multinational healthcare company that provides actionable molecular diagnostic information to personalize the diagnosis and treatment of cancer. Its tests are based on proprietary genomic, epigenetic, and other molecular technologies and assist physicians with the diagnosis of urologic cancers, the prognosis of recurrence risk, and prediction of response to a specific therapy. It derives revenues from clinical laboratory service testing or the out-licensing of the company's patented DNA methylation platform and biomarkers. Geographically, it derives revenue from the United States of America (USA), and Europe.